Securing the optimum launch price for a novel pharmaceutical product across 31 EU countries



SITUATION

Our client sought our expertise to support them in the development and submission of the optimum pricing dossiers for their novel product across 31 European markets covered by EMA's centralised procedure.

OUR OVERALL APPROACH



Landscape assessment



Evidence gap analysis



Launch price materials



Pricing dossier submissions

- ✓ Identified countryspecific P&R requirements relevant to our clients product
- ☑ Identified and mitigated gaps in product's evidence base
- ✓ Prepared launch price materials in line with the company P&R strategy
- Executed country specific pricing dossier submissions across the 31 EU countries

VALUE TO THE CLIENT



launch." | SENIOR DIRECTOR OF MARKETING



EMA: European Medicines Agency; P&R: Pricing and reimbursement